Edward Arrowsmith
Overview
Explore the profile of Edward Arrowsmith including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
284
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Choueiri T, Merchan J, Figlin R, Mcdermott D, Arrowsmith E, Michaelson M, et al.
Lancet Oncol
. 2025 Jan;
26(1):64-73.
PMID: 39756444
Background: Belzutifan, a first-in-class HIF-2α inhibitor, has shown antitumour activity as monotherapy and in combination with cabozantinib in patients with previously treated advanced kidney cancer. The phase 2 LITESPARK-003 study...
2.
Falchook G, Reeves J, Gandhi S, Spigel D, Arrowsmith E, George D, et al.
Cancer Immunol Immunother
. 2024 Mar;
73(4):72.
PMID: 38430405
Background: Inhibition of the adenosine 2A receptor (AR) diminishes the immunosuppressive effects of adenosine and may complement immune-targeting drugs. This phase 2 study evaluated the AR antagonist AZD4635 in combination...
3.
Stricker T, Jain N, Ma E, Yu E, Wang R, Schuldt R, et al.
Oncologist
. 2024 Feb;
29(6):534-542.
PMID: 38417095
Background: A recent real-world study observed that 24% of patients with advanced non-small cell lung cancer (aNSCLC) with actionable driver oncogenes (ADOs) initiated nontargeted therapies before biomarker test results became...
4.
Choueiri T, Mcdermott D, Merchan J, Bauer T, Figlin R, Heath E, et al.
Lancet Oncol
. 2023 Apr;
24(5):553-562.
PMID: 37011650
Background: Few treatment options are available for patients with advanced renal cell carcinoma who have received previous anti-PD-1-based or anti-PD-L1-based immunotherapy. Combining belzutifan, an HIF-2α inhibitor, with cabozantinib, a multitargeted...
5.
Schram A, Colombo N, Arrowsmith E, Narayan V, Yonemori K, Scambia G, et al.
JAMA Oncol
. 2022 Nov;
9(1):29-39.
PMID: 36394867
Importance: Nonclinical studies suggest that the combination of poly(ADP-ribose) polymerase and programmed cell death 1/programmed cell death-ligand 1 inhibitors has enhanced antitumor activity; however, the patient populations that may benefit...
6.
Caffrey M, Arrowsmith E
Am J Manag Care
. 2022 Jun;
28(3 Spec No.):SP102-SP103.
PMID: 35758890
No abstract available.
7.
Tykodi S, Gordan L, Alter R, Arrowsmith E, Harrison M, Percent I, et al.
J Immunother Cancer
. 2022 Feb;
10(2).
PMID: 35210307
Background: CheckMate 920 (NCT02982954) is a multicohort, phase 3b/4 clinical trial of nivolumab plus ipilimumab treatment in predominantly US community-based patients with previously untreated advanced renal cell carcinoma (RCC) and...
8.
Schleicher S, Chaudhry B, Dickson N, Aviki E, Arrowsmith E, Parikh R, et al.
JCO Oncol Pract
. 2021 Apr;
17(7):379-381.
PMID: 33872069
No abstract available.
9.
Herbst R, Arkenau H, Bendell J, Arrowsmith E, Wermke M, Soriano A, et al.
J Thorac Oncol
. 2020 Oct;
16(2):289-298.
PMID: 33068794
Introduction: Data of first-line ramucirumab plus pembrolizumab treatment of programmed death-ligand 1 (PD-L1)-positive NSCLC (cohort E) are reported (NCT02443324). Methods: In this multicenter, open-label phase 1a/b trial, patients received ramucirumab...
10.
Vogelzang N, Olsen M, McFarlane J, Arrowsmith E, Bauer T, Jain R, et al.
Clin Genitourin Cancer
. 2020 Jul;
18(6):461-468.e3.
PMID: 32718906
Background: The open-label phase IIIb/IV CheckMate 374 study (NCT02596035) was conducted to validate the safety and efficacy of flat-dose nivolumab 240 mg every 2 weeks (Q2W) in previously treated advanced/metastatic...